Corcept Therapeutics
CORT
109 hedge funds and large institutions have $250M invested in Corcept Therapeutics in 2016 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 43 increasing their positions, 24 reducing their positions, and 11 closing their positions.
127% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 11
79% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 24
24% more capital invested
Capital invested by funds: $201M → $250M (+$48.6M)
14% more funds holding
Funds holding: 96 → 109 (+13)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$5.97M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
+$1.75M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.72M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.36M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$1.61M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.61M |
| 3 |
TIM
Thornburg Investment Management
Santa Fe,
New Mexico
|
-$1.04M |
| 4 |
First Eagle Investment Management
New York
|
-$893K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$541K |
CORT Hedge Fund Activity: Q2 2016 in Review
109 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q2 2016, worth a combined $250M — up 24% from $201M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CORT positions and 11 closed out — a net gain of 14 holders — while 43 added to existing stakes and 24 trimmed.
The largest buyer was Invesco, adding an estimated $5.97M. The largest seller was BlackRock Institutional Trust, cutting an estimated $1.61M.
- 109 institutional investors held Corcept Therapeutics (CORT) as of Q2 2016, up from 96 in Q1 2016.
- Funds reported $250M of Corcept Therapeutics stock for Q2 2016, up 24% quarter-over-quarter.
- 25 funds opened new Corcept Therapeutics positions in Q2 2016 and 11 closed out, a net change of +14 holders.
- The largest Corcept Therapeutics buyer in Q2 2016 was Invesco, an estimated $5.97M added.
- The largest Corcept Therapeutics seller in Q2 2016 was BlackRock Institutional Trust, an estimated $1.61M sold.
Based on aggregated 13F filings for Q2 2016.